Abstract
The chemokine monocyte chemoattractant protein (MCP)-1 is an important mediator of monocyte infiltration in various solid tumours of epithelial origin. The aim of the present study was to evaluate the role of MCP-1 in the natural history of ovarian cancer and to determine its value as differentiation marker and prognostic marker regarding disease free and overall survival. This retrospective study comprises 86 patients with ovarian cancer, 48 with primary ovarian cancer and 38 with recurrent ovarian cancer, 67 patients with benign ovarian cysts and 42 healthy women. Median serum levels in patients with primary ovarian cancer, recurrent ovarian cancer, benign ovarian cysts and in healthy women were 535.6 (range 129.6–1200) pg ml–1, 427.3 (range 193.4–1101) pg ml–1, 371.2 (range 222–986.8) pg ml–1 and 318.7 (range 241.3–681.4) pg ml–1 respectively (Mann–Whitney U-test, P < 0.001). Univariate logistic regression models revealed a significant influence of MCP-1 serum levels on the odds of presenting with primary ovarian cancer versus benign cysts and versus healthy women respectively (univariate logistic regression, P < 0.001 and P < 0.001 respectively). In a multivariate logistic regression model considering MCP-1 and CA 125 serum levels simultaneously, both MCP-1 and CA 125 revealed statistical significance on the odds of presenting with primary ovarian cancer versus benign cysts (multivariate logistic regression, P = 0.05 and P < 0.001 respectively). In ovarian cancer patients, MCP-1 serum levels showed a statistically significant correlation with histological grade (Mann–Whitney U-test, P = 0.02) and age at the time of diagnosis (Mann–Whitney U-test, P = 0.03). Elevated MCP-1 serum levels prior to therapy were not associated with disease-free and overall survival (log-rank test, P = 0.2 and P = 0.7 respectively). In summary these data indicate that MCP-1 might play a functional role in the natural history of ovarian cancer and might serve as differentiation marker between benign ovarian cysts and ovarian cancer, providing additional information to the established tumour marker CA 125.
Article PDF
Similar content being viewed by others
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Amann, B, Perabo, FG, Wirger, A, Hugenschmidt, H & Chultze-Seeman, W (1998) Urinary levels of monocyte chemoattractant protein-1 correlate with tumor stage and grade in patients with bladder cancer. Br J Urol 82: 118–121.
Berek, J (1994). Epithelial ovarian cancer. In: Practical Gynecological Oncology, 2nd edn, Berek J and Hacker N (eds). Williams & Wilkins: Baltimore
Brunda, MJ, Sulich, V, Wright, RB & Palleroni, AV (1991) Tumoricidal activity and cytokine secretion by tumor-infiltrating macrophages. Int J Cancer 48: 704–708.
Chen, S & Lee, I (1984) Prognostic significance of morphology of tumor and retroperitoneal lymph nodes in epithelial carcinoma of the ovary. II. Correlation with survival. Gynecol Oncol 18: 94–99.
Desbaillets, I, Tada, M, De Tribolet, N, Diserens, AC, Hamou, MF & Van Meir, EG (1994) Human astrocytomas and glioblastomas express monocyte chemoattractant protein-1 (MCP-1) in vivo and vitro. Int J Cancer 58: 240–247.
Fidler, I & Schroit, A (1984) Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases. J Immunol 133: 515–518.
Graves, DT, Barnhill, R, Galanpoulos, T & Antonoades, HN (1992) Expression of monocyte chemoattractant protein-1 in human melanoma in vivo. Am J Pathol 140: 9–14.
Grimm, MC, Elsbury, SK, Pavli, P & Doe, WF (1996) Enhanced expression and production of monocyte chemoattractant protein-1 in iflammatory bowel disease. J Leukoc Biol 59: 804–812.
Haskill, S, Becker, S, Fowler, W & Walton, L (1982) Mononuclear-cell infiltration in ovarian cancer. I. Inflammatory-cell infiltrates from tumor and ascites material. Br J Cancer 45: 728–736.
Kuratsu, J, Yoshizato, K, Yoshimura, T, Leonard, EJ, Takeshima, H & Ushio, Y (1993) Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma. J Natl Cancer Inst 85: 1836–1839.
Leonard, EJ & Yoshimura, T (1990) Human monocyte chemoattractant protein-1 (MCP-1). Immunol Today 11: 97–101.
Mantovani, A (1994) Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab Invest 71: 5–16.
Mazzuccheli, L, Loetscher, P, Kapeller, A, Uguccioni, M, Baggiolini, M, Laissue, JA & Mueller, C (1996) Monocyte chemoattractant protein-1 gene expression in prostatic hyperplasia and prostate adenocarcinoma. Am J Pathol 149: 501–509.
Melani, C, Pupa, S, Stoppacciaro, A, Menard, S, Colnaghi, M, Parmiani, G & Colombo, M (1995) An in vivo model to compare human leukocyte infiltration in carcinoma xenografts producing different chemokines. Int J Cancer 62: 572–578.
Negus, R, Stamp, G, Hadley, YJ & Balkwill, F (1997) Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 150: 1723–1734.
Negus, R, Stamp, G, Relf, M, Burke, F, Malik, S, Bernasconi, S, Allavena, P, Sozzani, S, Mantovani, A & Balkwill, F (1995) The detection and localization of monocyte chemoattractant protein-1 (MCP-1) in human ovarian cancer. J Clin Invest 95: 2391–2396.
Negus, R, Turner, L, Burke, F & Balkwill, F (1998) Hypoxia down-regulates MCP-1 expression: implications for macrophage distribution in tumors. J Leukoc Biol 63: 758–765.
Peng, L, Shu, S & Krauss, JC (1997) Monocyte chemoattractant protein-1 inhibits the generation of tumor-reactive T cells. Cancer Res 57: 4849–4854.
Schall, T (1991) Biology of the RANTES/SIS cytokine family. Cytokine 3: 165–183.
Valkovic, T, Lucin, K, Krstulja, M, Dobi-Babic, R & Jonjic, N (1998) Expression of monocyte chemoattractant protein-1 in human invasive ductal breast cancer. Pathol Res Pract 194: 335–340.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Hefler, L., Tempfer, C., Heinze, G. et al. Monocyte chemoattractant protein-1 serum levels in ovarian cancer patients. Br J Cancer 81, 855–859 (1999). https://doi.org/10.1038/sj.bjc.6690776
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690776
- Springer Nature Limited
Keywords
This article is cited by
-
Role of CC-chemokine ligand 2 in gynecological cancer
Cancer Cell International (2022)
-
Purification of recombinant human chemokine CCL2 in E. coli and its function in ovarian cancer
3 Biotech (2021)
-
CCL2/CCR2 signaling in cancer pathogenesis
Cell Communication and Signaling (2020)
-
CCL2 secreted from cancer-associated mesothelial cells promotes peritoneal metastasis of ovarian cancer cells through the P38-MAPK pathway
Clinical & Experimental Metastasis (2020)
-
Serum levels of the chemokine CCL2 are elevated in malignant pleural mesothelioma patients
BMC Cancer (2019)